cancerBiology180x110

Vectibix Extends Survival in Colon Cancer

A Phase III study in patients with chemo-refractory colorectal cancer with wild-type K-ras genotype demonstrated that Amgen’s Vectibix (panitumumab) improved overall survival compared to best supportive therapy, alone. A total of 377 patients were randomized to receive best supportive care with or without intravenous infusions of Vectibix every 14 days. Full results of the study will be presented at a future medical meeting and submitted for publication. Continue reading

Lycera’s ROR-gamma agonists for cancer immunotherapy

Celgene and Lycera entered into a $105MM collaboration on its RORϒ agonists for the treatment of cancer, as well as LYC-30937, an oral gut-directed ATPase modulator now in early-stage clinical studies. LYC-30937 is designed to treat IBD without global immune suppression. Continue reading

cancerBiology180x110

What do pineapples, glucose, and cancer have in common – mitochondria

I was sent articles by two non-cancer researchers last week – they are quite fitting for discuss on this blog (thank you, Gina and Sherilyn). The first was on DCA (dichloroacetate), a drug approved for congenital lactic acidosis, and the second about bromelain, an enzyme in pineapples. Continue reading

cancerBiology180x110

Ibrance plus Faslodex Improves Outcomes in HR+ Breast Cancer

In a Phase 3 Paloma-III study of Pfizer’s CDK4/6 inhibitor (Ibrance – palbociclib) and an estrogen receptor antagonist (Faslodex – fulvestrant), patients receiving the combination had significantly prolonged progression-free survival than women with breast cancer who received Faslodex, alone. Continue reading

cancerBiology180x110

Prostate Cancer Genetic Map Unveiled

Researchers have identified a handful of mutations in patients with advanced prostate cancer for which therapeutics are already available, or in development. The genomes of 150 patients with metastatic (Stage 4) hormone-resistant disease were analyzed in order to develop a precision medicine framework for the treatment of advanced prostate cancer. Continue reading

cancerBiology180x110

Elotuzumab plus Revlimed and Dexamethasone in Multiple Myeloma

In the Phase III ELOQUENT-2 study, patients receiving elotuzumab plus standard therapy compared with patients receiving standard therapy alone, lived a median time of 19.4 months until their disease progressed or until they died, compared with 14.9 months in those who received standard therapy alone. In addition, at a median follow-up period of two years, elotuzumab reduced the risk of disease progression or death by 30 percent. Continue reading

cancerBiology180x110

Cancer-Associated Macrophage-Like Cells (CAML) – Liquid Biopsy for Cancer Diagnosis, Prognosis, Staging, and Monitoring

Cancers are tumors that cross the basement membrane and develop invasiveness, the ability to intravasate into blood vessels, and then to colonize and grow at distant sites. Complex heterotypic cellular interactions inside the tumor are responsible for this.

Dialog

Continue reading

cancerBiology180x110

Inhibitory RNA miR-182 Can Turn-Off Glioblastoma

Researchers examined large-scale genomic datasets and found that patients with higher levels of miR-182 had a better chance of surviving glioblastoma (GBM) longer. This prompted them to perform pre-clinical studies to elucidate the mechanism by which miR-182 acts. Continue reading